This page has only limited features, please log in for full access.

Unclaimed
Cristian Rodelo-Haad
Spanish Renal Research Network (REDinREN), Institute of Health Carlos III, 28029 Madrid, Spain

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 20 January 2021 in Nutrients
Reads 0
Downloads 0

In chronic kidney disease (CKD) patients, it would be desirable to reduce the intake of inorganic phosphate (P) rather than limit the intake of P contained in proteins. Urinary excretion of P should reflect intestinal absorption of P(inorganic plus protein-derived). The aim of the present study is to determine whether the ratio of urinary P to urinary urea nitrogen (P/UUN ratio) helps identify patients with a high intake of inorganic P.A cross-sectional study was performed in 71 patients affected by metabolic syndrome with CKD (stages 2–3) with normal serum P concentration. A 3-day dietary survey was performed to estimate the average daily amount and the source of P ingested. The daily intake ofPwas1086.5 ± 361.3mg/day; 64% contained in animal proteins, 22% in vegetable proteins, and 14% as inorganic P. The total amount of P ingested did not correlate with daily phosphaturia, but it did correlate with the P/UUN ratio (p < 0.018). Patients with the highest tertile of the P/UUN ratio >71.1 mg/g presented more abundant inorganic P intake (p < 0.038).The P/UUN ratio is suggested to be a marker of inorganic P intake. This finding might be useful in clinical practices to identify the source of dietary P and to make personalized dietary recommendations directed to reduce inorganic P intake.

ACS Style

María Pendón-Ruiz de Mier; Noemí Vergara; Cristian Rodelo-Haad; María López-Zamorano; Cristina Membrives-González; Rodrigo López-Baltanás; Juan Muñoz-Castañeda; Francisco Caravaca; Alejandro Martín-Malo; Arnold Felsenfeld; Eugenio De la Torre; Sagrario Soriano; Rafael Santamaría; Mariano Rodríguez. Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate/Urea Nitrogen Ratio in Urine. Nutrients 2021, 13, 292 .

AMA Style

María Pendón-Ruiz de Mier, Noemí Vergara, Cristian Rodelo-Haad, María López-Zamorano, Cristina Membrives-González, Rodrigo López-Baltanás, Juan Muñoz-Castañeda, Francisco Caravaca, Alejandro Martín-Malo, Arnold Felsenfeld, Eugenio De la Torre, Sagrario Soriano, Rafael Santamaría, Mariano Rodríguez. Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate/Urea Nitrogen Ratio in Urine. Nutrients. 2021; 13 (2):292.

Chicago/Turabian Style

María Pendón-Ruiz de Mier; Noemí Vergara; Cristian Rodelo-Haad; María López-Zamorano; Cristina Membrives-González; Rodrigo López-Baltanás; Juan Muñoz-Castañeda; Francisco Caravaca; Alejandro Martín-Malo; Arnold Felsenfeld; Eugenio De la Torre; Sagrario Soriano; Rafael Santamaría; Mariano Rodríguez. 2021. "Assessment of Inorganic Phosphate Intake by the Measurement of the Phosphate/Urea Nitrogen Ratio in Urine." Nutrients 13, no. 2: 292.

Review
Published: 16 March 2020 in Toxins
Reads 0
Downloads 0

Fibroblast Growth Factor 23 (FGF23) and Klotho play an essential role in the regulation of mineral metabolism, and both are altered as a consequence of renal failure. FGF23 increases to augment phosphaturia, which prevents phosphate accumulation at the early stages of chronic kidney disease (CKD). This effect of FGF23 requires the presence of Klotho in the renal tubules. However, Klotho expression is reduced as soon as renal function is starting to fail to generate a state of FGF23 resistance. Changes in these proteins directly affect to other mineral metabolism parameters; they may affect renal function and can produce damage in other organs such as bone, heart, or vessels. Some of the mechanisms responsible for the changes in FGF23 and Klotho levels are related to modifications in the Wnt signaling. This review examines the link between FGF23/Klotho and Wnt/β-catenin in different organs: kidney, heart, and bone. Activation of the canonical Wnt signaling produces changes in FGF23 and Klotho and vice versa; therefore, this pathway emerges as a potential therapeutic target that may help to prevent CKD-associated complications.

ACS Style

Juan Rafael Muñoz-Castañeda; Cristian Rodelo-Haad; Maria Victoria Pendon-Ruiz De Mier; Alejandro Martin-Malo; Rafael Santamaria; Mariano Rodriguez. Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease. Toxins 2020, 12, 185 .

AMA Style

Juan Rafael Muñoz-Castañeda, Cristian Rodelo-Haad, Maria Victoria Pendon-Ruiz De Mier, Alejandro Martin-Malo, Rafael Santamaria, Mariano Rodriguez. Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease. Toxins. 2020; 12 (3):185.

Chicago/Turabian Style

Juan Rafael Muñoz-Castañeda; Cristian Rodelo-Haad; Maria Victoria Pendon-Ruiz De Mier; Alejandro Martin-Malo; Rafael Santamaria; Mariano Rodriguez. 2020. "Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease." Toxins 12, no. 3: 185.

Journal article
Published: 12 February 2020 in Clinical Kidney Journal
Reads 0
Downloads 0

Background In dialysis patients, non-adherence to oral cinacalcet adds complexity to the control of secondary hyperparathyroidism. The present study aims to evaluate the use of intravenous calcimimetic, etelcalcetide, in the control of secondary hyperparathyroidism in patients adherent and non-adherent to oral calcimimetics. Method The Simplified Medication Adherence Questionnaire was used to identify non-adherence. Almost half of the patients were non-adherent to the treatment with cinacalcet. Twenty-five patients (15 non-adherent) were switched from cinacalcet to etelcalcetide and were followed-up monthly for 8 months. Results Cinacalcet was discontinued for 1 week before the initiation of etelcalcetide. After this period, the serum PTH levels increased by2-fold in adherent patients, whereas it did not change in non-adherent patients suggesting that they were not taking the medication. Etelcalcetide progressively reduced serum parathyroid hormone (PTH) (mean ± standard deviation) from 818 ± 395 to 367 ± 289 pg/mL (P < 0.001) in non-adherents, and from 496 ± 172 to 228 ± 111 pg/mL (P < 0.01) in adherent patients with a mean dose of 7.0 ± 2.3 and 5.1 ± 1.2 mg in non-adherent and in adherent patients, respectively. Etelcalcetide increased the percentage of patients with PTH on target from 28% to 58%. Patients with serum calcium <8.4 mg/dL increased from 8% to 40%, although they remained asymptomatic. The percent of patients with serum phosphate on target increased from 40% to 65%. Conclusion The lack of adherence to cinacalcet is a possible cause of the apparent lack of response to oral calcimimetic. The use of etelcalcetide ensures compliance and control of secondary hyperparathyroidism in both non-adherent and adherent patients.

ACS Style

Maria Dolores Arenas; Cristian Rodelo-Haad; M Victoria Pendón-Ruiz de Mier; Mariano Rodriguez. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics. Clinical Kidney Journal 2020, 14, 840 -846.

AMA Style

Maria Dolores Arenas, Cristian Rodelo-Haad, M Victoria Pendón-Ruiz de Mier, Mariano Rodriguez. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics. Clinical Kidney Journal. 2020; 14 (3):840-846.

Chicago/Turabian Style

Maria Dolores Arenas; Cristian Rodelo-Haad; M Victoria Pendón-Ruiz de Mier; Mariano Rodriguez. 2020. "Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics." Clinical Kidney Journal 14, no. 3: 840-846.

Journal article
Published: 11 December 2019 in Clinica Chimica Acta
Reads 0
Downloads 0

Chronic kidney disease (CKD) is associated with a wide number of abnormalities in mineral metabolism. Often, these alterations are the leading players in the development of comorbidities associated with CKD, which are risk factors of mortality. In this context, mineral and bone disorder associated with CKD (CKD-MBD) are highlighted, connecting bone, renal, and cardiovascular disorders. Many studies have been led to propose strategies to avoid, reduce, or slow down CKD-MBD progression using different compositions of metallic elements-based P binders such as aluminum, magnesium, or calcium. Magnesium, the aim of this review, has been used by nephrologists to treat CKD-MBD with a variable acceptation due mainly to different results on bone homeostasis. Nowadays, we have new evidence about the efficacy of magnesium supplementation on vascular calcification, renal function, and bone disorders, suggesting potential beneficial effects of Magnesium in the management of CKD-MBD.

ACS Style

M.V. Pendón-Ruiz de Mier; Cristian Rodelo-Haad; J.M. Díaz-Tocados; J.R. Muñoz-Castañeda; M. Rodríguez. Magnesium: An old player revisited in the context of CKD-MBD. Clinica Chimica Acta 2019, 501, 53 -59.

AMA Style

M.V. Pendón-Ruiz de Mier, Cristian Rodelo-Haad, J.M. Díaz-Tocados, J.R. Muñoz-Castañeda, M. Rodríguez. Magnesium: An old player revisited in the context of CKD-MBD. Clinica Chimica Acta. 2019; 501 ():53-59.

Chicago/Turabian Style

M.V. Pendón-Ruiz de Mier; Cristian Rodelo-Haad; J.M. Díaz-Tocados; J.R. Muñoz-Castañeda; M. Rodríguez. 2019. "Magnesium: An old player revisited in the context of CKD-MBD." Clinica Chimica Acta 501, no. : 53-59.

Breast images
Published: 06 June 2019 in The Breast Journal
Reads 0
Downloads 0
ACS Style

Cristian Rodelo‐Haad; Elvira Esquivias‐Motta; Francisco Amaral‐Neiva; Alejandro Martin‐Malo; Pedro Aljama; Mariano Rodriguez. Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy. The Breast Journal 2019, 25, 998 -999.

AMA Style

Cristian Rodelo‐Haad, Elvira Esquivias‐Motta, Francisco Amaral‐Neiva, Alejandro Martin‐Malo, Pedro Aljama, Mariano Rodriguez. Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy. The Breast Journal. 2019; 25 (5):998-999.

Chicago/Turabian Style

Cristian Rodelo‐Haad; Elvira Esquivias‐Motta; Francisco Amaral‐Neiva; Alejandro Martin‐Malo; Pedro Aljama; Mariano Rodriguez. 2019. "Reversing extraosseous calcifications. A case of breast uremic calcific arteriolopathy." The Breast Journal 25, no. 5: 998-999.

Review
Published: 22 March 2019 in Toxins
Reads 0
Downloads 0

Fibroblast growth factor 23 (FGF23) plays a key role in the complex network between the bones and other organs. Initially, it was thought that FGF23 exclusively regulated phosphate and vitamin D metabolism; however, recent research has demonstrated that an excess of FGF23 has other effects that may be detrimental in some cases. The understanding of the signaling pathways through which FGF23 acts in different organs is crucial to develop strategies aiming to prevent the negative effects associated with high FGF23 levels. FGF23 has been described to have effects on the heart, promoting left ventricular hypertrophy (LVH); the liver, leading to production of inflammatory cytokines; the bones, inhibiting mineralization; and the bone marrow, by reducing the production of erythropoietin (EPO). The identification of FGF23 receptors will play a remarkable role in future research since its selective blockade might reduce the adverse effects of FGF23. Patients with chronic kidney disease (CKD) have very high levels of FGF23 and may be the population suffering from the most adverse FGF23-related effects. The general population, as well as kidney transplant recipients, may also be affected by high FGF23. Whether the association between FGF23 and clinical events is causal or casual remains controversial. The hypothesis that FGF23 could be considered a therapeutic target is gaining relevance and may become a promising field of investigation in the future.

ACS Style

Cristian Rodelo-Haad; Rafael Santamaria; Juan R. Muñoz-Castañeda; M. Victoria Pendón-Ruiz De Mier; Alejandro Martin-Malo; Mariano Rodriguez. FGF23, Biomarker or Target? Toxins 2019, 11, 175 .

AMA Style

Cristian Rodelo-Haad, Rafael Santamaria, Juan R. Muñoz-Castañeda, M. Victoria Pendón-Ruiz De Mier, Alejandro Martin-Malo, Mariano Rodriguez. FGF23, Biomarker or Target? Toxins. 2019; 11 (3):175.

Chicago/Turabian Style

Cristian Rodelo-Haad; Rafael Santamaria; Juan R. Muñoz-Castañeda; M. Victoria Pendón-Ruiz De Mier; Alejandro Martin-Malo; Mariano Rodriguez. 2019. "FGF23, Biomarker or Target?" Toxins 11, no. 3: 175.

Journal article
Published: 11 March 2019 in Kidney International
Reads 0
Downloads 0

Calcimimetics decrease parathyroid hormone (PTH) secretion in patients with secondary hyperparathyroidism. The decrease in PTH should cause a reduction in bone turnover; however, the direct effect of calcimimetics on bone cells, which express the calcium-sensing receptor (CaSR), has not been defined. In this study, we evaluated the direct bone effects of CaSR activation by a calcimimetic (AMG 641) in vitro and in vivo. To create a PTH "clamp," total parathyroidectomy was performed in rats with and without uremia induced by 5/6 nephrectomy, followed by a continuous subcutaneous infusion of PTH. Animals were then treated with either the calcimimetic or vehicle. Calcimimetic administration increased osteoblast number and osteoid volume in normal rats under a PTH clamp. In uremic rats, the elevated PTH concentration led to reduced bone volume and increased bone turnover, and calcimimetic administration decreased plasma PTH. In uremic rats exposed to PTH at 6-fold the usual replacement dose, calcimimetic administration increased osteoblast number, osteoid surface, and bone formation. A 9-fold higher dose of PTH caused an increase in bone turnover that was not altered by the administration of calcimimetic. In an osteosarcoma cell line, the calcimimetic induced Erk1/2 phosphorylation and the expression of osteoblast genes. The addition of a calcilytic resulted in the opposite effect. Moreover, the calcimimetic promoted the osteogenic differentiation and mineralization of human bone marrow mesenchymal stem cells in vitro. Thus, calcimimetic administration has a direct anabolic effect on bone that counteracts the decrease in PTH levels.

ACS Style

Juan M. Díaz-Tocados; María E. Rodríguez-Ortiz; Yolanda Almadén; Carmen Pineda; Julio M. Martínez-Moreno; Carmen Herencia; Noemi Vergara; M. Victoria Pendón-Ruiz de Mier; Rafael Santamaría; Cristian Rodelo-Haad; Antonio Casado-Díaz; Víctor Lorenzo; Catarina Carvalho; João M. Frazão; Arnold J. Felsenfeld; William G. Richards; Escolástico Aguilera-Tejero; Mariano Rodríguez; Ignacio López; Juan R. Muñoz-Castañeda. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney International 2019, 95, 1064 -1078.

AMA Style

Juan M. Díaz-Tocados, María E. Rodríguez-Ortiz, Yolanda Almadén, Carmen Pineda, Julio M. Martínez-Moreno, Carmen Herencia, Noemi Vergara, M. Victoria Pendón-Ruiz de Mier, Rafael Santamaría, Cristian Rodelo-Haad, Antonio Casado-Díaz, Víctor Lorenzo, Catarina Carvalho, João M. Frazão, Arnold J. Felsenfeld, William G. Richards, Escolástico Aguilera-Tejero, Mariano Rodríguez, Ignacio López, Juan R. Muñoz-Castañeda. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney International. 2019; 95 (5):1064-1078.

Chicago/Turabian Style

Juan M. Díaz-Tocados; María E. Rodríguez-Ortiz; Yolanda Almadén; Carmen Pineda; Julio M. Martínez-Moreno; Carmen Herencia; Noemi Vergara; M. Victoria Pendón-Ruiz de Mier; Rafael Santamaría; Cristian Rodelo-Haad; Antonio Casado-Díaz; Víctor Lorenzo; Catarina Carvalho; João M. Frazão; Arnold J. Felsenfeld; William G. Richards; Escolástico Aguilera-Tejero; Mariano Rodríguez; Ignacio López; Juan R. Muñoz-Castañeda. 2019. "Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration." Kidney International 95, no. 5: 1064-1078.

Multicenter study
Published: 01 March 2019 in Clinical Microbiology and Infection
Reads 0
Downloads 0

Monitoring for CMV-specific CMI in intermediate-risk KT recipients must be regular to reflect dynamic changes in overall immunosuppression and individual susceptibility. The early assessment at post-transplant day 15 remains particularly informative.

ACS Style

Mario Fernández-Ruiz; Estela Giménez; Víctor Vinuesa; Tamara Ruiz-Merlo; Patricia Parra; Paula Amat; Miguel Montejo; Aurora Páez-Vega; Sara Cantisan; Julián Torre-Cisneros; Jesús Fortún; Amado Andres; Rafael San Juan; Francisco López-Medrano; David Navarro; José María Aguado; Esther González; Natalia Polanco; Regino Rodríguez; Maitane Aranzamendi; Oriana Carmona; Rosa Escudero; Pilar Martín-Dávila; Ana Fernández; Rocío Aguado; Elisa Vidal; Maria Luisa Agüera; Alberto Rodriguez-Benot; Cristian Rodelo-Haad. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clinical Microbiology and Infection 2019, 25, 381.e1 -381.e10.

AMA Style

Mario Fernández-Ruiz, Estela Giménez, Víctor Vinuesa, Tamara Ruiz-Merlo, Patricia Parra, Paula Amat, Miguel Montejo, Aurora Páez-Vega, Sara Cantisan, Julián Torre-Cisneros, Jesús Fortún, Amado Andres, Rafael San Juan, Francisco López-Medrano, David Navarro, José María Aguado, Esther González, Natalia Polanco, Regino Rodríguez, Maitane Aranzamendi, Oriana Carmona, Rosa Escudero, Pilar Martín-Dávila, Ana Fernández, Rocío Aguado, Elisa Vidal, Maria Luisa Agüera, Alberto Rodriguez-Benot, Cristian Rodelo-Haad. Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment. Clinical Microbiology and Infection. 2019; 25 (3):381.e1-381.e10.

Chicago/Turabian Style

Mario Fernández-Ruiz; Estela Giménez; Víctor Vinuesa; Tamara Ruiz-Merlo; Patricia Parra; Paula Amat; Miguel Montejo; Aurora Páez-Vega; Sara Cantisan; Julián Torre-Cisneros; Jesús Fortún; Amado Andres; Rafael San Juan; Francisco López-Medrano; David Navarro; José María Aguado; Esther González; Natalia Polanco; Regino Rodríguez; Maitane Aranzamendi; Oriana Carmona; Rosa Escudero; Pilar Martín-Dávila; Ana Fernández; Rocío Aguado; Elisa Vidal; Maria Luisa Agüera; Alberto Rodriguez-Benot; Cristian Rodelo-Haad. 2019. "Regular monitoring of cytomegalovirus-specific cell-mediated immunity in intermediate-risk kidney transplant recipients: predictive value of the immediate post-transplant assessment." Clinical Microbiology and Infection 25, no. 3: 381.e1-381.e10.

Research article
Published: 22 February 2019 in PLOS ONE
Reads 0
Downloads 0

Pancreatic autoantibodies (AAb) has been associated with a worse pancreas graft survival after simultaneous pancreas-kidney transplantation (SPK). However, due to the variable time for AAb to become positive and the lack of early biomarkers suggesting such autoimmune activation, the mechanisms leading ß-cell destruction remain uncertain. The present study aimed to evaluate the association between post-transplant AAb and the functional impairment of the pancreatic ß-cell and also the association of such AAb with inflammation after SPK. In a longitudinal study, we analyzed the impact of post-transplant glutamic acid decarboxylase (GAD-65) and the insulinoma-associated autoantigen 2 (IA-2) AAb on pancreas graft function. Serum Hb1Ac and C-peptide (C-pep) were longitudinally compared between a group with positive posttransplant AAb (AAb+; n = 40) and another matched group with negative AAb (AAb-; n = 40) until the fifth year following seroconversion. In the cross-sectional analysis, we further evaluated the systemic signatures of inflammation by measuring pro-inflammatory CD14+CD16+ monocytes by flow-cytometry and interleukin 17-A serum levels in 38 SPK recipients and ten healthy controls. In the longitudinal study, patients with AAb+ showed higher levels of Hb1Ac (p<0.001) and lower C-pep levels (p<0.001) compared to those who remained AAb- throughout the follow-up. In the cross-sectional study, AAb+ patients showed a higher percentage of CD14+CD16+ monocytes compared with those with AAb- and the healthy controls (6.70±4.19% versus 4.0±1.84% and 3.44±0.93%; p = 0.026 and 0.009 respectively). Also, CD14+CD16+ monocytes correlated with Hb1Ac and C-pep serum levels. Multivariate logistic regression showed that posttransplant AAb+ was independently associated with a higher percentage of pro-inflammatory monocytes (adjusted-OR 1.59, 95%CI 1.05–2.40, p = 0.027). The group of patients with positive AAb also showed higher levels of IL17A as compared with the other groups (either healthy control or the negative AAb subjects). In conclusion, pancreatic AAb+ after SPK were not only associated with higher Hb1Ac and lower c-peptide serum levels but also with an increased percentage of CD14+CD16+ monocytes and higher levels of circulating IL17-A.

ACS Style

Cristian Rodelo-Haad; Maria Luisa Agüera; Andres Carmona; Maria Dolores Navarro; Julia Carracedo; Alberto Rodriguez-Benot; Pedro Aljama. Pancreatic autoantibodies and CD14+CD16+ monocytes subset are associated with the impairment of ß-cell function after simultaneous pancreas-kidney transplantation. PLOS ONE 2019, 14, e0212547 .

AMA Style

Cristian Rodelo-Haad, Maria Luisa Agüera, Andres Carmona, Maria Dolores Navarro, Julia Carracedo, Alberto Rodriguez-Benot, Pedro Aljama. Pancreatic autoantibodies and CD14+CD16+ monocytes subset are associated with the impairment of ß-cell function after simultaneous pancreas-kidney transplantation. PLOS ONE. 2019; 14 (2):e0212547.

Chicago/Turabian Style

Cristian Rodelo-Haad; Maria Luisa Agüera; Andres Carmona; Maria Dolores Navarro; Julia Carracedo; Alberto Rodriguez-Benot; Pedro Aljama. 2019. "Pancreatic autoantibodies and CD14+CD16+ monocytes subset are associated with the impairment of ß-cell function after simultaneous pancreas-kidney transplantation." PLOS ONE 14, no. 2: e0212547.

Journal article
Published: 11 December 2018 in Nefrología (English Edition)
Reads 0
Downloads 0

We aimed to assess the effectiveness of ambulatory blood pressure monitoring (ABPM) and subclinical target organ damage parameters for diagnosis of resistant hypertension (RH). We assessed demographic and anthropometric variables, the incidence of cardiovascular events and subclinical target organ damage (n = 112). We also studied the relationship between these variables and the ABPM results. Of the 112 patients referred from primary care with a diagnosis of RH, 69 (61.6%) were confirmed by ABPM. We found statistically significant differences (p < 0.001) between patients with RH and pseudo-resistant hypertension in the appearance of subclinical target organ damage. A percentage of 84 of the patients had microalbuminuria: 66.25 ± 30.7 mg/dl); 44.9% had stage 3 chronic kidney disease: the average glomerular filtration was 59 ml/min/1.73 m2; and 56.5% had left ventricular hypertrophy on echocardiography. Fundoscopy revealed that 64% of the patients had hypertensive retinopathy. Three variables were associated with an increased HR risk: microalbuminuria, hypertensive retinopathy and left ventricular hypertrophy (OR 5.7, 6.2 and 11.2, respectively). This study shows that the systematic testing for target organ damage, particularly in terms of albuminuria, is a simple and inexpensive tool, with a high predictive value for RH (85%), which could be useful for prioritizing patients who need ABPM. El presente estudio tiene como objetivo destacar la importancia de la monitorización ambulatoria de la presión arterial (MAPA) y de los parámetros de lesión subclínica de órgano diana en el diagnóstico de hipertensión refractaria (HR). Se estudiaron pacientes con diagnóstico de HR (n = 112). Se analizaron variables demográficas, antropométricas, riesgo cardiovascular y lesión subclínica de órgano diana y se relacionaron con la confirmación de HR a través de la MAPA. Del total de 112 pacientes con el diagnóstico de HR derivados desde atención primaria se confirmaron mediante MAPA el 61,6% de los casos (n = 69). Se observaron diferencias estadísticamente significativas (p < 0,001) en la aparición de lesión subclínica de órgano diana en los hipertensos refractarios respecto a los pseudorrefractarios. Un 84% de los pacientes con HR presentaban microalbuminuria: 66,25 ± 30,7 mg/dl). El 44,9% tienen una enfermedad renal crónica estadio 3 con filtrado glomerular medio de 59 ml/min/1,73 m2. El 56,5% presentaba hallazgos ecocardiográficos de hipertrofia de ventrículo izquierdo. El examen de fondo de ojo reveló que un 64% de los pacientes presentaban retinopatía hipertensiva. Las 3 variables que se asociaron a mayor riesgo de HR fueron la presencia de microalbuminuria, retinopatía hipertensiva e hipertrofia de ventrículo izquierdo por ecocardiograma (OR 5,7, 6,2 y 11,2, respectivamente). Nuestro estudio demuestra que la búsqueda sistemática de daño de órgano diana, especialmente en lo referente a albuminuria, es una herramienta sencilla y barata, con un valor predictivo de HR alto (85%). Podría ser de utilidad en circunstancias en las que es necesario priorizar la realización de MAPA.

ACS Style

M. Inmaculada Poveda García; M. Dolores Del Pino Y Pino; Raquel Alarcón Rodriguez; Cristian Rodelo-Haad; Tesifón Parrón Carreño. The value of ABPM and subclinical target organ damage parameters in diagnosis of resistant hypertension. Nefrología (English Edition) 2018, 39, 67 -72.

AMA Style

M. Inmaculada Poveda García, M. Dolores Del Pino Y Pino, Raquel Alarcón Rodriguez, Cristian Rodelo-Haad, Tesifón Parrón Carreño. The value of ABPM and subclinical target organ damage parameters in diagnosis of resistant hypertension. Nefrología (English Edition). 2018; 39 (1):67-72.

Chicago/Turabian Style

M. Inmaculada Poveda García; M. Dolores Del Pino Y Pino; Raquel Alarcón Rodriguez; Cristian Rodelo-Haad; Tesifón Parrón Carreño. 2018. "The value of ABPM and subclinical target organ damage parameters in diagnosis of resistant hypertension." Nefrología (English Edition) 39, no. 1: 67-72.

Research article
Published: 12 September 2018 in PLOS ONE
Reads 0
Downloads 0

In pregnant women, the use of Mycophenolic acid (MPA) is associated with teratogenicity. Recently, the European Medicines Agency (EMEA) and the Spanish Agency of Medicine and Sanitary Products (AEMPS) warned about the potential teratogenic effects of MPA. These adverse events may occur even in children from males on treatment with MPA. However, evidence of malformations in offsprings of male kidney transplanted patients (KT) exposed to MPA is limited. Thus, the present study aimed to evaluate the incidence of offspring malformations in children of renal transplanted males under MPA. We conducted a retrospective study in which we evaluated the incidence of malformations in descendants from male recipients that were exposed or not to MPA before and at the time of conception. Two groups of patients were evaluated. Those exposed to MPA (MPA group, n = 20) and the non-MPA group (n = 13) that included patients that did not receive AZA (n = 5) and eight that did receive AZA (n = 8) at the time of conception. A total of forty-nine post-transplant conceptions were identified from 33 different renal transplanted males. MPA was used as the immunosuppressant in 28 of the conceptions. Males from the non-MPA group fathered the other 21 children. Median time from grafting to conception was 6.1 (IQR 2.4–11.1) years, and it was similar between groups. There were eight miscarriage episodes, 2 in the non-MPA group and 6 in the MPA group although differences were not reached. After that, all patients had children without problems. No malformations were detected in any of the 49 regardless whether they were exposed or not to MPA. No evidence of MPA-associated malformations was observed in descendants of kidney transplanted males on treatment with MPA. Further research is warranted to confirm our findings to properly advice transplanted males keen to procreate.

ACS Style

Isabel Lopez-Lopez; Cristian Rodelo-Haad; Maria Luisa Agüera; Rosario Cabello-Jabalquinto; Elvira Esquivias-Motta; M. Dolores Navarro; Pedro Aljama; Alberto Rodriguez-Benot. Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males. PLOS ONE 2018, 13, e0202589 .

AMA Style

Isabel Lopez-Lopez, Cristian Rodelo-Haad, Maria Luisa Agüera, Rosario Cabello-Jabalquinto, Elvira Esquivias-Motta, M. Dolores Navarro, Pedro Aljama, Alberto Rodriguez-Benot. Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males. PLOS ONE. 2018; 13 (9):e0202589.

Chicago/Turabian Style

Isabel Lopez-Lopez; Cristian Rodelo-Haad; Maria Luisa Agüera; Rosario Cabello-Jabalquinto; Elvira Esquivias-Motta; M. Dolores Navarro; Pedro Aljama; Alberto Rodriguez-Benot. 2018. "Administration of mycophenolic acid is not associated with malformations in descendants from kidney transplanted males." PLOS ONE 13, no. 9: e0202589.

Research article
Published: 07 August 2018 in PLOS ONE
Reads 0
Downloads 0

In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate 4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation.

ACS Style

Cristian Rodelo-Haad; Maria E. Rodríguez-Ortiz; Alejandro Martin-Malo; M. Victoria Pendon-Ruiz de Mier; M. Luisa Agüera; Juan R. Muñoz-Castañeda; Sagrario Soriano; Francisco Caravaca; M. Antonia Alvarez-Lara; Arnold Felsenfeld; Pedro Aljama; Mariano Rodriguez. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLOS ONE 2018, 13, e0201537 .

AMA Style

Cristian Rodelo-Haad, Maria E. Rodríguez-Ortiz, Alejandro Martin-Malo, M. Victoria Pendon-Ruiz de Mier, M. Luisa Agüera, Juan R. Muñoz-Castañeda, Sagrario Soriano, Francisco Caravaca, M. Antonia Alvarez-Lara, Arnold Felsenfeld, Pedro Aljama, Mariano Rodriguez. Phosphate control in reducing FGF23 levels in hemodialysis patients. PLOS ONE. 2018; 13 (8):e0201537.

Chicago/Turabian Style

Cristian Rodelo-Haad; Maria E. Rodríguez-Ortiz; Alejandro Martin-Malo; M. Victoria Pendon-Ruiz de Mier; M. Luisa Agüera; Juan R. Muñoz-Castañeda; Sagrario Soriano; Francisco Caravaca; M. Antonia Alvarez-Lara; Arnold Felsenfeld; Pedro Aljama; Mariano Rodriguez. 2018. "Phosphate control in reducing FGF23 levels in hemodialysis patients." PLOS ONE 13, no. 8: e0201537.

Evaluation study
Published: 01 March 2018 in Transplantation Proceedings
Reads 0
Downloads 0

24-hour proteinuria (24h-P) has been the most widespread test for clinical follow-up of proteinuria after kidney transplantation (KT), but urine collection is often not properly collected. Spot protein-creatinine ratio (P/Cr) has become the alternative to 24h-P for proteinuria evaluation in many KT units. However, its reliability, equivalence to 24h-P, and prognostic value regarding allograft outcome remain unknown. Therefore, the aim of this study was to evaluate the correlation and agreement between both methods for assessing proteinuria and to analyze which of them is a better predictor of graft survival. We collected proteinuria measurements from KT patients in our center. 24h-P was adjusted for body surface area. Pearson correlation test and the Bland-Altman method were used to analyze correlation and agreement. Survival analysis was performed with the use of the Kaplan-Meier method and multivariate Cox proportional hazard model. A total of 8,549 urine samples were analyzed from 472 patients in whom 24h-P and P/Cr were simultaneously measured. A significant correlation was observed between 24h-P and P/Cr (r = .76; P < .001); however, the agreement between methods showed that P/Cr overestimated proteinuria compared with 24h-P, particularly when the latter was >1 g/24 h. The Cox regression multivariate model showed an increased risk of graft loss associated with proteinuria when assessed by either 24h-P (hazard ratio [HR] 6.53, 95% confidence interval [CI] 2.49–17.1) or P/Cr (HR 3.34, 95% CI 1.04–10.7). P/Cr is an method interchangeable with 24h-P for detecting proteinuria after KT. When proteinuria increases, the P/Cr overestimates 24h-P, even though it also has a significant and similar prognostic value for predicting graft survival.

ACS Style

C. Rodelo-Haad; E. Esquivias-Motta; M.L. Agüera; P. Aljama; A. Rodríguez-Benot. 24-Hour Proteinuria Versus Spot Protein-Creatinine Ratio for Kidney Transplant Management in Clinical Practice. Transplantation Proceedings 2018, 50, 560 -564.

AMA Style

C. Rodelo-Haad, E. Esquivias-Motta, M.L. Agüera, P. Aljama, A. Rodríguez-Benot. 24-Hour Proteinuria Versus Spot Protein-Creatinine Ratio for Kidney Transplant Management in Clinical Practice. Transplantation Proceedings. 2018; 50 (2):560-564.

Chicago/Turabian Style

C. Rodelo-Haad; E. Esquivias-Motta; M.L. Agüera; P. Aljama; A. Rodríguez-Benot. 2018. "24-Hour Proteinuria Versus Spot Protein-Creatinine Ratio for Kidney Transplant Management in Clinical Practice." Transplantation Proceedings 50, no. 2: 560-564.

Case reports
Published: 01 January 2018 in Kidney International
Reads 0
Downloads 0
ACS Style

Cristian Rodelo-Haad; Maria L. Agüera; Rosa Ortega; Ana Martinez-Lopez; M. Dolores Navarro; Alberto Rodriguez-Benot; Pedro Aljama. Lithium-associated nephropathy in the renal allograft. Kidney International 2018, 93, 273 .

AMA Style

Cristian Rodelo-Haad, Maria L. Agüera, Rosa Ortega, Ana Martinez-Lopez, M. Dolores Navarro, Alberto Rodriguez-Benot, Pedro Aljama. Lithium-associated nephropathy in the renal allograft. Kidney International. 2018; 93 (1):273.

Chicago/Turabian Style

Cristian Rodelo-Haad; Maria L. Agüera; Rosa Ortega; Ana Martinez-Lopez; M. Dolores Navarro; Alberto Rodriguez-Benot; Pedro Aljama. 2018. "Lithium-associated nephropathy in the renal allograft." Kidney International 93, no. 1: 273.

Original research article
Published: 31 October 2017 in Frontiers in Immunology
Reads 0
Downloads 0

The consolidation of single antigens beads (SAB-panIgG) assay in the detection of preformed anti-HLA antibodies has improved transplantation success. However, its high sensitivity has limited the allograft allocation for sensitized patients, increasing their waiting time. A modification of the standard SAB-panIgG assay allows the detection of that sub-set of antibodies capable of binding C1q (SAB-C1q assay). However, the clinical usefulness of SAB-C1q assay for determining the unacceptable mismatches is under discussion. We retrospectively analyzed the impact of preformed donor-specific anti-HLA antibodies (DSA) according to the C1q-binding ability on allograft outcome, examining 389 single-kidney transplanted patients from deceased donors. Recipients with preformed C1q-binding DSA showed the lowest allograft survival up to 7-years (40.7%) compared to patients with preformed non-C1q-binding DSA (73.4%; p=0.001) and without DSA (79.1%; p<0.001). Allograft survival rate was similar between patients with preformed non-C1q-binding DSA and patients without preformed DSA (p=0.403). Interestingly, among the high-MFI DSA (≥10,000) population (n=46), those patients whose DSA were further capable of binding C1q showed a poorer allograft outcome (38.4% vs. 68.9%; p=0.041). Moreover, in our multivariate predictive model for assessing the risk of allograft-loss, the presence of C1q-binding DSA (HR 4.012; CI 95% 2.326-6.919; p<0.001), but not of non-C1q-binding DSA (HR 1.389; CI 95% 0.784-2.461; p=0.260) remained an independent predictor after stratifying the DSA population according to the C1q-binding ability and adjusting the model for other pre-transplantation predictive factors including donor age, cold-ischemia time and HLA-DR mismatches. In conclusion, the unacceptable mismatch definition according to the SAB-C1q assay would improve the risk stratification of allograft loss and increase the limited allograft allocation of highly sensitized patients, shortening their waiting time.

ACS Style

Juan Molina; Ana Navas; María-Luisa Agüera; Cristian Rodelo-Haad; Corona Alonso; Alberto Rodríguez-Benot; Pedro Aljama; Rafael Solana. Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome. Frontiers in Immunology 2017, 8, 1 .

AMA Style

Juan Molina, Ana Navas, María-Luisa Agüera, Cristian Rodelo-Haad, Corona Alonso, Alberto Rodríguez-Benot, Pedro Aljama, Rafael Solana. Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome. Frontiers in Immunology. 2017; 8 ():1.

Chicago/Turabian Style

Juan Molina; Ana Navas; María-Luisa Agüera; Cristian Rodelo-Haad; Corona Alonso; Alberto Rodríguez-Benot; Pedro Aljama; Rafael Solana. 2017. "Impact of Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibody C1q-Binding Ability on Kidney Allograft Outcome." Frontiers in Immunology 8, no. : 1.

Conference paper
Published: 01 November 2016 in Transplantation Proceedings
Reads 0
Downloads 0

Infection of the urinary tract (UTI) is the most common form of bacterial infection in renal transplant patients, but its management is still controversial. We compared symptomatic and asymptomatic bacteriuria, treated or untreated, during two different months (summer or winter). This longitudinal, prospective study involved routine urine cultures collected during September 2014 or March 2015. Demographic, clinical, and microbiological characteristics from the patients with positive urine cultures were described. The main outcomes were the need of hospitalization, the bacterial clearance, and the selection of the resistant pathogen. From the 538 urine cultures collected, only 61 were positive urine cultures. Twenty were untreated asymptomatic bacteriuria (AB), 28 were treated AB, and 13 were treated symptomatic bacteriuria. The more prevalent micro-organisms were E coli (27%), K pneumoniae (11%), and E faecalis (7%). There were no differences in the demographic, clinical, and microbiological characteristics depending on the month when the urine cultures were collected. Only 10 patients required hospitalization during follow-up, and all of them belonged to the treated group. Bacterial clearance after the treatment occurred in 20 patients of the 41 treated (48.9%) and spontaneously in 14 of the 20 patients untreated (70%). Of the treated patients, 47.6% developed a new resistance to another antibiotic. Only 7.6% of the routine urine cultures on renal transplant were positive. Untreated AB did not require hospitalization, and 70% had spontaneous bacterial clearance.

ACS Style

N. Arencibia; M.L. Agüera; Cristian Rodelo-Haad; I. López; M. Sánchez-Agesta; A. Hurtarte; M.D. Navarro; A. Rodríguez-Benot. Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients. Transplantation Proceedings 2016, 48, 2941 -2943.

AMA Style

N. Arencibia, M.L. Agüera, Cristian Rodelo-Haad, I. López, M. Sánchez-Agesta, A. Hurtarte, M.D. Navarro, A. Rodríguez-Benot. Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients. Transplantation Proceedings. 2016; 48 (9):2941-2943.

Chicago/Turabian Style

N. Arencibia; M.L. Agüera; Cristian Rodelo-Haad; I. López; M. Sánchez-Agesta; A. Hurtarte; M.D. Navarro; A. Rodríguez-Benot. 2016. "Short-Term Outcome of Untreated Versus Treated Asymptomatic Bacteriuria in Renal Transplant Patients." Transplantation Proceedings 48, no. 9: 2941-2943.

Original article
Published: 03 February 2015 in Arabian Archaeology and Epigraphy
Reads 0
Downloads 0

This cross‐sectional study analyzes factors associated with the development of CMV‐specific CD8+ response, measured by IFNg production after cytomegalovirus (CMV) peptide stimulation, in CMV‐seropositive solid organ transplantation candidates. A total of 114 candidates were enrolled, of whom 22.8% (26/114) were nonreactive (IFNγ < 0.2 IU/mL). Multivariate logistic regression analysis showed that age, HLA alleles and organ to be transplanted were associated with developing CMV‐specific CD8+ immunity (reactive; IFNγ ≥ 0.2 IU/mL). The probability of being reactive was higher in candidates over 50 than in those under 50 (OR 6.33, 95%CI 1.93–20.74). Candidates with HLA‐A1 and/or HLA‐A2 alleles had a higher probability of being reactive than those with non‐HLA‐A1/non‐HLA‐A2 alleles (OR 10.97, 95%CI 3.36–35.83). Renal candidates had a higher probability of being reactive than lung (adjusted OR 8.85, 95%CI 2.24–34.92) and liver candidates (OR 4.87, 95%CI 1.12–21.19). The AUC of this model was 0.84 (p < 0.001). Positive and negative predictive values were 84.8% and 76.9%, respectively. In renal candidates longer dialysis was associated with an increased frequency of reactive individuals (p = 0.040). Therefore, although the assessment of CMV‐specific CD8+ response is recommended in all R+ candidates, it is essential in those with a lower probability of being reactive, such as non‐renal candidates, candidates under 50 or those with non‐HLA‐A1/non‐HLA‐A2 alleles.

ACS Style

S. Cantisán; Cristian Rodelo-Haad; A. Páez-Vega; A. Nieto; J. M. Vaquero; A. Poyato; M. Montejo; M. C. Fariñas; Antonio Rivero; Rafael Solana; A. Martín-Malo; J. Torre-Cisneros. Factors Related to the Development of CMV-Specific CD8+ T cell Response in CMV-Seropositive Solid Organ Transplant Candidates. Arabian Archaeology and Epigraphy 2015, 15, 715 -722.

AMA Style

S. Cantisán, Cristian Rodelo-Haad, A. Páez-Vega, A. Nieto, J. M. Vaquero, A. Poyato, M. Montejo, M. C. Fariñas, Antonio Rivero, Rafael Solana, A. Martín-Malo, J. Torre-Cisneros. Factors Related to the Development of CMV-Specific CD8+ T cell Response in CMV-Seropositive Solid Organ Transplant Candidates. Arabian Archaeology and Epigraphy. 2015; 15 (3):715-722.

Chicago/Turabian Style

S. Cantisán; Cristian Rodelo-Haad; A. Páez-Vega; A. Nieto; J. M. Vaquero; A. Poyato; M. Montejo; M. C. Fariñas; Antonio Rivero; Rafael Solana; A. Martín-Malo; J. Torre-Cisneros. 2015. "Factors Related to the Development of CMV-Specific CD8+ T cell Response in CMV-Seropositive Solid Organ Transplant Candidates." Arabian Archaeology and Epigraphy 15, no. 3: 715-722.

Evaluation study
Published: 01 January 2015 in Transplantation Proceedings
Reads 0
Downloads 0

The pathogenesis of type 1 diabetes mellitus (T1DM) is associated with auto-antibodies. These auto-antibodies contribute to pancreatic ß-cell destruction. Tyrosine-phosphatases (IA-2) and glutamic acid decarboxylase (GAD65) are the most frequently used by clinicians. When T1DM patients develops advanced chronic kidney disease, simultaneous pancreas-kidney (SPK) transplantation becomes the best option. However, pancreatic graft survival is limited. The role of the auto-antibodies on pancreas graft survival remains controversial.

ACS Style

Cristian Rodelo-Haad; M.L. Agüera; S. Martinez-Vaquera; M.V. Pendon-Ruiz De Mier; M.D. Salmeron-Rodriguez; E. Esquivias; M.D. Navarro; A. Rodriguez-Benot; P. Aljama. Tyrosine-Phosphatase and Glutamate-Decarboxylase Antibodies After Simultaneous Pancreas Kidney Transplantation: Do They Have an Impact on Pancreas Graft Survival? Transplantation Proceedings 2015, 47, 107 -111.

AMA Style

Cristian Rodelo-Haad, M.L. Agüera, S. Martinez-Vaquera, M.V. Pendon-Ruiz De Mier, M.D. Salmeron-Rodriguez, E. Esquivias, M.D. Navarro, A. Rodriguez-Benot, P. Aljama. Tyrosine-Phosphatase and Glutamate-Decarboxylase Antibodies After Simultaneous Pancreas Kidney Transplantation: Do They Have an Impact on Pancreas Graft Survival? Transplantation Proceedings. 2015; 47 (1):107-111.

Chicago/Turabian Style

Cristian Rodelo-Haad; M.L. Agüera; S. Martinez-Vaquera; M.V. Pendon-Ruiz De Mier; M.D. Salmeron-Rodriguez; E. Esquivias; M.D. Navarro; A. Rodriguez-Benot; P. Aljama. 2015. "Tyrosine-Phosphatase and Glutamate-Decarboxylase Antibodies After Simultaneous Pancreas Kidney Transplantation: Do They Have an Impact on Pancreas Graft Survival?" Transplantation Proceedings 47, no. 1: 107-111.

Journal article
Published: 10 April 2014
Reads 0
Downloads 0

Percutaneous renal biopsy (PRB) is a key invasive technique in the study of kidney disease and it is associated with considerable morbidity. Retrospective studies have shown minor complications in 10%-20% and major complications in 1.2%-6.6% of cases. However, this aspect has not been studied prospectively. The aim of our study was to prospectively assess complications related to PRB in the native kidney. From January 2009 to May 2013, we prospectively analysed PRB performed by nephrologists in native kidneys under ultrasound guidance. We analysed clinical and laboratory variables. We defined minor complications as the decrease in haemoglobin (Hb) of more than 1g/dL and major complications as the need for a transfusion or invasive technique. 241 PRB were performed over this period. The mean patient age was 49 years (±17), the majority (56%) were male and 58.1% had high blood pressure. In 51% of cases, we carried out 2 punctures. There were minor complications in 46 patients (19.1%) and major complications in 9 patients (3.7%). In the univariate analysis, pre-PRB Hb was 10.3g/dL (±1.3) in patients with major complications and 12.3g/dL (±2.2) in the remaining patients (p=.003); in the multivariate analysis: OR 0.51, 95% CI (0.2-0.9), p<.05. PRB is a procedure that is not without risk, since minor complications occurred in 19.1% and major complications in 3.7% of cases. Pre-PRB Hb is an independent risk factor for the development of major complications.

ACS Style

M Victoria Pendón-Ruiz De Mier; Mario Espinosa-Hernández; Cristian Rodelo-Haad; Elvira Esquivias-De Motta; José Gómez-Carrasco; Rosa Ortega; Pedro Aljama. Estudio prospectivo de las complicaciones asociadas a la biopsia percutánea en riñón nativo: experiencia en un centro. 2014, 34, 383 -7.

AMA Style

M Victoria Pendón-Ruiz De Mier, Mario Espinosa-Hernández, Cristian Rodelo-Haad, Elvira Esquivias-De Motta, José Gómez-Carrasco, Rosa Ortega, Pedro Aljama. Estudio prospectivo de las complicaciones asociadas a la biopsia percutánea en riñón nativo: experiencia en un centro. . 2014; 34 (34):383-7.

Chicago/Turabian Style

M Victoria Pendón-Ruiz De Mier; Mario Espinosa-Hernández; Cristian Rodelo-Haad; Elvira Esquivias-De Motta; José Gómez-Carrasco; Rosa Ortega; Pedro Aljama. 2014. "Estudio prospectivo de las complicaciones asociadas a la biopsia percutánea en riñón nativo: experiencia en un centro." 34, no. 34: 383-7.

Comparative study
Published: 01 December 2013 in Transplantation Proceedings
Reads 0
Downloads 0

Renal dysfunction is a common complication of advanced liver failure and liver transplantation. Since the introduction of the MELD criteria the proportion of patients with advanced chronic kidney disease and need for liver transplantation has increased. One alternative is the combined liver-kidney transplant (CLKT). The aim of this study was to evaluate the outcome of this type of transplant in our center.

ACS Style

Cristian Rodelo-Haad; A. Rodriguez-Benot; S. Martinez-Vaquera; M.D. Navarro-Cabello; M.L. Aguera-Morales; M.V. Pendon Ruiz De Mier; J.L. Montero-Álvarez; M. De La Mata-García; J. Briceño-Delgado; P. Aljama-Garcia. Combined Liver-Kidney Transplantation: Survey of a Single Center in Spain. Transplantation Proceedings 2013, 45, 3640 -3643.

AMA Style

Cristian Rodelo-Haad, A. Rodriguez-Benot, S. Martinez-Vaquera, M.D. Navarro-Cabello, M.L. Aguera-Morales, M.V. Pendon Ruiz De Mier, J.L. Montero-Álvarez, M. De La Mata-García, J. Briceño-Delgado, P. Aljama-Garcia. Combined Liver-Kidney Transplantation: Survey of a Single Center in Spain. Transplantation Proceedings. 2013; 45 (10):3640-3643.

Chicago/Turabian Style

Cristian Rodelo-Haad; A. Rodriguez-Benot; S. Martinez-Vaquera; M.D. Navarro-Cabello; M.L. Aguera-Morales; M.V. Pendon Ruiz De Mier; J.L. Montero-Álvarez; M. De La Mata-García; J. Briceño-Delgado; P. Aljama-Garcia. 2013. "Combined Liver-Kidney Transplantation: Survey of a Single Center in Spain." Transplantation Proceedings 45, no. 10: 3640-3643.